{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-012545","form_type":"8-K","ticker":"ERNA","cik":"0000748592","company_name":"Ernexa Therapeutics Inc.","filed_at":"2023-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.971532+00:00","generated_at":"2026-06-17T23:20:08.689159+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Eterna Therapeutics posts FY2022 net loss $24.6M; licenses iPSC tech to Lineage, subleases BMS space","bullets":["Net loss for Q4 2022 was $4.5M ($1.24 per share); full year net loss $24.6M ($8.06 per share).","Cash and restricted cash $15.5M as of Dec 31, 2022; $4.1M restricted for BMS sublease.","Entered income-generating license agreement with Lineage Cell Therapeutics for gene-edited iPSC lines for neurology indications.","Subleased 45,000 sq. ft. from BMS at Cambridge Crossing; BMS provides $8.6M for build-out.","Appointed Matt Angel, Ph.D. as permanent CEO and President (previously interim)."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-012545","json":"https://secwatch.observer/filing/0001140361-23-012545.json","markdown":"https://secwatch.observer/filing/0001140361-23-012545.md","text":"https://secwatch.observer/filing/0001140361-23-012545.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/748592/000114036123012545/0001140361-23-012545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/748592/000114036123012545/brhc10050022_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T23:20:08.689159+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"22851b7adef58767360e8958d0764dbf9a2f59fb","claim":"Ernexa Therapeutics Inc. reported full year of 2022 results: net income For the full year of 2022, net loss was $24.6 million, or $8.06 per share., EPS $8.06 per share.","evidence_excerpt":"For the full year of 2022, net loss was $24.6 million, or $8.06 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036123012545/0001140361-23-012545-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year of 2022"},{"label":"Net income","value":"For the full year of 2022, net loss was $24.6 million, or $8.06 per share."},{"label":"EPS","value":"$8.06 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"948b1c530f196da6a3fc1857548a7e76e6a51652","claim":"Ernexa Therapeutics Inc. reported fourth quarter of 2022 results: net income Net loss for the fourth quarter of 2022 was $4.5 million, or $1.24 per share, EPS $1.24 per share.","evidence_excerpt":"Net loss for the fourth quarter of 2022 was $4.5 million, or $1.24 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036123012545/0001140361-23-012545-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter of 2022"},{"label":"Net income","value":"Net loss for the fourth quarter of 2022 was $4.5 million, or $1.24 per share"},{"label":"EPS","value":"$1.24 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}